inactivated SARS-CoV-2 vaccine (COVID-19 Vaccine (Vero Cell) Inactivated) / Jiangsu Rec-Biotech - LARVOL DELTA

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV) (clinicaltrials.gov) - P2 | N=300 | Completed | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Recruiting ➔ Completed | Phase classification: P2/3 ➔ P2

Phase classification • Trial completion • Infectious Disease • Novel Coronavirus Disease

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV) (clinicaltrials.gov) - P2/3 | N=300 | Recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Active, not recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV) (clinicaltrials.gov) - P2/3 | N=300 | Active, not recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | N=1950 ➔ 300 | Trial primary completion date: Feb 2023 ➔ Aug 2022

Enrollment change • Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease